

Changes to your plan's pharmacy drug list

In our ongoing effort to assist you in maximizing your health care investment while offering your plan members clinically appropriate prescription therapy, we are announcing changes to the **Standard Control Formulary + Advanced Control Specialty Formulary** effective **April 1, 2026**. A copy of the Performance Drug List is attached for your reference

The formulary review process focused on many factors, including:

Adding products that have demonstrated enhanced clinical efficacy and/or provide more convenient dosage forms.

Formulary additions

Drug Class	Drug Name(s)
Endocrine and Metabolic, Calcium Regulators*	BONSITY [^] , OSPOMYV [^] , STOBOCLO [^]

Removing products that may have less convenient dosage forms, more side effects or cost more than other available options on the CVS Caremark[®] Drug List.

Formulary exclusions

Drug Class	Drug Name(s)	Formulary Alternative(s)
Endocrine and Metabolic, Calcium Regulators*	FORTEO**, PROLIA	teriparatide, zoledronic acid, BONSITY, OSPOMYV, STOBOCLO, TYMLOS
Endocrine and Metabolic, Thyroid Agents*	ARMOUR THYROID, NP THYROID	levothyroxine, liothyronine

Tier 2 to Tier 3

Drug Class	Drug Name(s)	Formulary Alternative(s)
Anti-Infectives, Erythromycins, Macrolides	DIFICID**	fidaxomicin
Central Nervous System, Multiple Sclerosis Agents	COPAXONE**	dimethyl fumarate delayed-rel, fingolimod, glatiramer, teriflunomide, AVONEX, BAFIERTAM, BETASERON, KESIMPTA, MAYZENT, OCREVUS, REBIF, TYSABRI, ZEPOSIA
Endocrine and Metabolic, Antiobesity	SAXENDA**	liraglutide, orlistat, QSYMIA, WEGOVY
Hematologic, Platelet Aggregation Inhibitors	BRILINTA**	clopidogrel, prasugrel, ticagrelor

Key for table

UPPER CASE = brand-name medication

lower case = generic medication

*Class has existing formulary exclusions

**Multi-source Brand Product

[^]Previously New to Market Block

Please note: The specialty copay may not be affected by the proposed changes if the plan has a fixed copay for all specialty drugs.

Mailing Process:

As always, notifications will be sent to members who are negatively affected by tier changes* or drug exclusions. Please encourage your members to use the CVS Caremark website, Caremark.com, to view the most current version of the drug list, as well as to review their prescription drug benefit information, request mail service orders and research drug information.

We appreciate the opportunity to serve you and your members' prescription benefit needs. If you have any questions regarding these changes, please do not hesitate to contact me.



*Except in the case of products that have generic equivalents available or are acute therapies.